HAVCR2 and acute lymphoblastic leukemia: reported overexpression of TIM-3 alone and in combination with PD-1 on CD4+ T cells in the bone marrow with no significant difference in T cell subpopulations, and defined TIM-3 as a substantial prognostic risk factor for relapse in B-ALL patients (65).